Skip to main content

HB 3086

AN ACT relating to requirements for pharmaceutical drug manufacturers to

House Bill
Filed

Filed

Bill introduced by legislator

Committee

Hearing

Passed Cmte

Calendar

Passed

Sent

Enrolled

Governor

Signed

89th Regular Session

Jan 14, 2025 - Jun 2, 2025 • Session ended

Awaiting Committee Assignment

Bill filed, pending referral to House committee

← Back to Bills

Committee

Not yet assigned

Fiscal Note

Not available

What This Bill Does

Pharmaceutical drug manufacturers in Texas must submit an annual report detailing prescription drug costs, including wholesale acquisition cost information for FDA-approved drugs that have experienced significant price increases (40% over three years or 15% in one year). The report must provide specific details such as drug type, reasons for cost increases, research and development expenses, newly approved drugs, and drugs that have lost patent exclusivity. The Texas Department of State Health Services will publish this cost increase information within 60 days of receiving the report, increasing transparency around prescription drug pricing.

Subject Areas

Bill Text

relating to requirements for pharmaceutical drug manufacturers to
report prescription drug costs.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
SECTION 1.  Section 441.0051, Health and Safety Code, is
Sec. 441.0051.  ANNUAL REPORT.  (a)  Not later than the 15th
day of each calendar year, a pharmaceutical drug manufacturer shall
submit a report to the department stating the current wholesale
acquisition cost information for the United States Food and Drug
Administration-approved prescription drugs sold in or into this
(b)  For a prescription drug with a wholesale acquisition
cost increase of 40 percent or more over the drug's wholesale
acquisition cost in the preceding three calendar years or 15
percent or more in the preceding calendar year, a pharmaceutical
drug manufacturer shall include in the annual report required under
(1)  information on whether the prescription drug is a
brand name drug or generic version of a brand name drug;
(2)  a statement on each factor that caused the
increase in the wholesale acquisition cost and an explanation of
the impact of each factor on the cost;
(3)  aggregate, research, and development costs as
filed with United States Securities and Exchange Commission on Form
10-K for the most recent calendar year for which final audit data is
(4)  the name of each of the manufacturer's
prescription drugs the United States Food and Drug Administration
approved in the previous three calendar years; and
(5)  the name of each of the manufacturer's
prescription drugs that lost patent exclusivity in the United
States in the previous three calendar years.
(c)  The information a pharmaceutical drug manufacturer
submits to the department under Subsections (a) and (b) must be
consistent with the information the manufacturer includes in the
manufacturer's annual consolidated report filed with the United
States Securities and Exchange Commission on Form 10-K or any other
SECTION 2.  Section 441.0054, Health and Safety Code, is
Sec. 441.0054.  PUBLICATION OF COST INCREASE INFORMATION.
Not later than the 60th day after receipt of the report submitted
under Section 441.0051 [or 441.0053(a)], the department shall
publish the required cost increase information [required by Section
441.0053] on the department's prescription drug price information
SECTION 3.  Section 441.0102(a), Health and Safety Code, is
(a)  The department shall [may] assess an administrative
penalty against a person who violates this chapter or a rule adopted
SECTION 4.  Section 441.0053, Health and Safety Code, is
SECTION 5.  As soon as practicable after the effective date
of this Act, the executive commissioner of the Health and Human
Services Commission shall adopt rules necessary to implement the
changes in law made by this Act.
SECTION 6.  This Act takes effect September 1, 2025.

Bill History

filed

Bill filed: AN ACT relating to requirements for pharmaceutical drug manufacturers to